RECEIVED CENTRAL FAX CENTER

JUN. 21. 2006 11:37AM

BMS PATENT DEPT

JUN 2 1 2006

NO. 5224 P. 4

CASE D0029NP

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office (571-273-8300) on the date shown below.

Stephen C. D'Amico

Type or print name

Signanure

June 21, 2006

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

PEREZ-VILLAR

Examiner: MERTZ, PREMA MARIA

APPLICATION NO: 09/966,955 FILED: SEPTEMBER 28, 2001

FOR: IDENTIFICATION AND CLONING OF A FULL-LENGTH

HUMAN CLNK-RELATED GENE, MIST (MAST CELL

IMMUNORECEPTOR SIGNAL TRANSDUCER)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT WITHOUT TRAVERSE

Sir:

In reply to the Office Action dated May 11, 2006, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention of Group I, without traverse, drawn to a nucleic acids encoding a protein of the amino acid sequence set forth in SEQ ID NO:2 and fragments thereof, vectors and recombinant host cells comprising the same, in addition to methods of making the receptor polypeptide.

The Office Action further directs Applicants to elect a single polypeptide which is encoded by the elected polynucleotides from either SEQ ID NO:2, 4, or 6. Although Applicants believe the Examiner's request is most in view of each of Groups 1 to 21 being directed to either SEQ ID NO:2, 4 or 6, directly or indirectly, Applicants hereby provisionally elect, without

RECEIVED CENTRAL FAX CENTER

JUN. 21. 2006 11:37AM

BMS PATENT DEPT

JUN 2 1 2006

NO. 5224 P. 5

CASE D0029NP

traverse, polynucleotides of Group I encoding the polypeptide sequence provided as SEQ ID NO:2 and fragments thereof. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

A one-month extension is hereby requested pursuant to 37 CFR §1.136(a). Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$120 for payment of the extension fee.

If any fee is due in connection herewith, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: June 21, 2006

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652